Corporate presentation coming soon
About Mosaic IE
Mosaic Immunoengineering is a biotechnology company focused on developing and eventually commercializing our proprietary technology to activate the innate immune system. Our lead product candidate, MIE-101, is based on a naturally occurring plant virus that is non-infectious in animals and humans but acts as strong adjuvant that activates Toll-like receptors 2, 4 and 7 through its natural immune recognition. When injected into a tumor, MIE-101 naturally triggers the body’s innate immune system, thereby altering the tumor microenvironment and directing activated anti-tumor T cells to attack both the injected tumor as well as other tumors throughout the body. Research related to these immune-oncology applications has been well funded and published in leading scientific journals We are also employing this same natural adjuvant to produce modular vaccines that can prevent diseases by linking the virus directly to target antigens of interest. In preclinical studies, vaccination with these agents has been able to protect animals from both cancer and infectious diseases and has shown significant promise against SARS-CoV-2. These vaccines also have a superior cold-chain profile that would potentially allow distribution to vaccination centers without refrigeration or freezing. Our goal is to advance these technologies into human and veterinary studies in early 2022.